Abstract Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm showing aberrant bone marrow remodeling with increased angiogenesis, progressive matrix accumulation, and fibrosis development. Thrombospondins (TSP) are factors sharing pro-fibrotic and anti-angiogenic properties, and have not been addressed in PMF before. We investigated the expression of TSP-1 and TSP-2 in PMF related to the stage of myelofibrosis (n=51) and in individual follow-up biopsies by real-time PCR, immunohistochemistry, and confocal laser scanning microscopy (CLSM). TSP-1 was significantly overexpressed (p<0.05) in all stages of PMF when compared to controls. Individual follow-up biopsies showed involvement of TSP-1 during progressive myelofibrosis. TSP-2 was barely detectable but 40% of cases with advanced myelofibrosis showed a strong expression. Megakaryocytes and interstitial proplatelet formations were shown to be the relevant source for TSP-1 in PMF. Stroma cells like endothelial cells and fibroblasts showed no TSP-1 labeling when double-immunofluorescence staining and CLSM were applied. Based on its dual function, TSP-1 in PMF is likely to be a mediator within a pro-fibrotic environment which discriminates from ET cases. On the other hand, TSP-1 is a factor acting (ineffectively) against exaggerated angiogenesis. Both features suggest TSP-1 to be a biomarker for monitoring a PMF-targeted therapy.
Introduction
Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm with features like clustering of atypical and enlarged megakaryocytes, exaggerated formation of new vessels, abnormal progenitor cell trafficking, and the high risk to develop manifest myelofibrosis [1] .
Megakaryocytes are known to harbor large amounts of different biologically active factors [2] . Megakaryocytes in PMF are clonal and apparently responsible for a majority of the reactive changes demonstrable in the aberrant bone marrow architecture [3] . The bone marrow in PMF is thought to be pervaded by numerous megakaryocytederived growth factors and cytokines lastly leading to a reactive pro-angiogenic and pro-fibrotic environment [4] .
Thrombospondins (TSP) were identified in thrombinstimulated platelets and are expressed by a variety of cells such as endothelial cells, fibroblasts, and smooth muscle cells [5] . TSP are so-called matricellular proteins, i.e., they can interact with cell surface receptors and with components of the extracellular matrix thereby mediating cellmatrix interactions [6] . TSP-1 and TSP-2 are trimers of about 145 kDa and belong to one subgroup. TSP-3, TSP-4, TSP-5 are much smaller with about 100 kDa in size. The latter are not fully investigated yet, and their roles might be distinct from TSP-1 and TSP-2.
An important pro-angiogenic factor in PMF is VEGF [7, 8] whereas factors with anti-angiogenic properties in PMF have not been investigated yet. Two members of the TSP family, i.e. TSP-1 and TSP-2, are mediators of an antiangiogenic response. TSP-1 was shown to prevent the formation of new vessels by inhibition of VEGF and stromal cell-derived factor-1 (SDF-1), [9] . However, there is some experimental evidence suggesting that TSP-1 can also promote angiogenesis in vitro. This promotion could be correlated with the action of active matrix metalloproteinase-9 (MMP-9) and might depend on its concentration and the in vitro model used [10] .
Interestingly, TSP-1 is also known as an activator of TGFβ-1 which is the most relevant inducer of fibroblast activation and matrix synthesis in the fibrotic response and in PMF [11, 12] . TSP-1 also inhibits the activity of MMPs which are primarily involved in proteolysis of collagens and other matrix components. From this point of view, any aberrant expression could contribute to a particular hallmark in PMF, i.e., increased angiogenesis in case of TSP-1 down-regulation and development of myelofibrosis when TSP-1 action is abrogated.
TSP are also involved in proper megakaryocyte development and platelet function, i.e. TSP-2 deficiency was shown to impair the connection of megakaryocyte proplatelet formations with bone marrow sinuses which led to exaggerated interstitial fragmentation [13] . This study revealed that TSP-2 in megakaryocytes was almost entirely the result of an uptake from the bone marrow microenvironment rather than de novo synthesis.
We were interested in the expression level and cellular sources of TSP-1 and TSP-2 in PMF, and aimed to get insights in the role of TSP in PMF-related changes of the bone marrow architecture. In addition, TSP expression in essential thrombocythemia (ET) as a MPN with very low risk of fibrosis development should be compared with PMF and controls.
Material and methods

Bone marrow study group
Formalin-fixed and paraffin-embedded (FFPE) bone marrow trephines with PMF (n=51), ET (n=10), chronic myelomonocytic leukemia (CMML; n=11), and chronic myelogenous leukemia (CML; n=10) diagnosed according to the World Health Organization (WHO) criteria 2008 [14] were retrieved from the bone marrow registry of the Institute of Pathology, Hannover Medical School. Three PMF groups were established according to the presence and degree of myelofibrosis (MF) as determined by silver impregnation (Gomori) according to standard procedures [15] . Accordingly, PMF cases were assigned to a group of hypercellular, prefibrotic PMF (MF0, n=20), a group showing demonstrable increase of reticulin fibers (MF1, n=12), and cases with advanced myelofibrosis and osteosclerosis (MF2/3, n=19). Individual PMF follow-up biopsies (n=5, up to four core biopsies per case; median: three biopsies) ranging from 1 to 7 years (median: 3 years) were also analyzed. Criteria of selection for follow-up biopsies was that the first diagnostic biopsy should either show no fibrosis (MF0, n=3) or already demonstrable myelofibrosis (MF2/3, n=2) .
Biopsies of the control group (n=12) were clinically indicated to exclude an involvement by peripheral lymphoma (n=7) and metastasis of small cell lung carcinoma (n=1) or because of splenomegaly (n=1), Budd-Chiari syndrome (n=1), or leukocytopenia (n=2). All biopsies showed no evidence for a neoplasm or any other disease and were diagnosed as "hematopoiesis in line with age".
Quantification of potential mutant allele burden of JAK2 (V617F) and MPL (W515L/K) in PMF was performed using Pyrosequencing® assays as described [16] . CML cases all showed presence of BCR-ABL fusion gene. Clinical parameter of patients and controls including molecular status of JAK2 and MPL are shown in Table 1 .
Real-time RT-PCR
RNA extracted from bone marrow core biopsies [17] was transcribed into the complementary DNA by means of the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Real-time RT-PCR was performed on an ABI PRISM 7500 Fast Real-time PCR System (Applied Biosystems, Foster City, CA, USA) using the individual TaqMan Gene Expression Assays for thrombospondin-1 (THBS-1, Hs00962908_m1, 59-bp amplicon) and thrombospondin-2 (THBS-2, Hs01568065_m1, 63-bp amplicon), the reference genes β-GUS (β-Glucuronidase, GUSB, Hs99999908_m1, 81-bp amplicon), and RNA polymerase 2A (POLR2A: Hs00172187_m1, 61-bp amplicon); all assays were purchased from Applied Biosystems, Foster City, CA, USA.
Statistics
The sample-and detector-specific evaluations of amplification curves of the ABI PRISM 7500 Fast Real-time PCR System were statistically analyzed with Prism 5.0 (GraphPad Software, San Diego, CA, USA) by applying the nonparametric Kruskal-Wallis test followed by Dunn's post-test. P values ≤0.05 were displayed as statistically significant.
Immunohistochemistry
Immunohistochemistry was performed using the ZytoChem-Plus HRP Polymer-Kit, and visualization was performed with the DAB Substrate Kit High Contrast kit (both from Zytomed Systems GmbH, Berlin, Germany). Counterstaining was accomplished with haematoxylin. Bone marrow sections (2-3 μm) were deparaffinized in xylol including incubation with 3% H 2 O 2 for 10 min, pre-treated in a pressure cooker (3 min, 125°C, in 10-mmol/l pH 6.0 citrate buffer) and incubated for 1 h with a monoclonal mouse anti-human Thrombospondin-1 antibody (1:100 dilution, ab1823, abcam, Cambridge, UK) and a monoclonal mouse anti-human Thrombospondin-2 antibody (1:200 dilution, MAB1635, R&D Systems). Kidney tissue was used as the TSP-1 positive control. TSP-2 stained colon carcinoma cells in a hepatic metastasis which was used as the positive control.
Double-immunofluorescence staining
For double-immunofluorescence staining, FFPE sections (2-3 μm) were processed as shown for conventional immunohistochemistry with the TSP-1 antibody and by application of a CD105/Endoglin antibody (1:50 dilution, RB-9291-P, Thermo Scientific, Fremont, CA, USA). Visualization was achieved by incubation of the secondary antibody for 30 min (1:100 dilution, Cy™2-conjugated AffiniPure F (ab') 2 Fragment Donkey Anti Mouse IgG (H+L), 715-226-150, dianova, Hamburg, Germany; 1:100 dilution, Cy™3-conjugated AffiniPure F(ab') 2 Fragment Donkey Anti Rabbit IgG (H + L), 711-166-152, dianova, Hamburg, Germany). Nuclear counterstaining was achieved by staining with Hoechst blue. An isotype control monoclonal/ polyclonal antibody (1:100 dilution, negative control for mouse IgG 1 Ab-1, clone NCG01, DLN-05791, dianova, Hamburg, Germany; 1:100 dilution, negative control for rabbit IgG Ab-1, DLN-13121, dianova, Hamburg, Germany) was used as negative control in lieu of the primary antibody.
Confocal laser scan microscopy
Bone marrow sections were investigated by using a confocal laser scanning microscope (Leica DM IRB with a TCS SP2 AOBS scan head, Leica, Heidelberg, Germany, provided by the core facility for laser microscopy at the Hannover Medical School; MHH). The microscope is equipped with a 405-nm laser for excitation of blue dyes, a 543-nm laser for red dyes and a 488-nm laser for excitation of green dyes. Images were recorded in a resolution of a 40× objective and analyzed by using the Leica Confocal Software (LCS-Lite 2.61; Leica, Heidelberg, Germany).
Results
Overexpression of TSP-1 in all stages of disease TSP-1 mRNA was overexpressed in all stages of disease independently of the degree of myelofibrosis. Cases showing no demonstrable fiber increase overexpressed We also tested CML and CMML for TSP-2 mRNA expression. However, the yield of detectable signals was low, i.e. only 20% of the cases showed a notable signal. We therefore resigned from further investigation and illustration of results of TSP-2 mRNA in CML and CMML (data not shown).
Individual courses in PMF showed involvement of TSP-1 in progressive myelofibrosis
We monitored the expression level of TSP-1 mRNA in five individual courses of PMF showing progressive remodeling of the bone marrow, i.e. changes in the degree of myelofibrosis. All courses showed considerable TSP-1 dynamics during development of myelofibrosis (3, 4, 5) or ongoing matrix remodeling (2), respectively (Fig. 3) . Follow-up 1 started with an exaggerated TSP-1 overexpression of 29-fold at MF0 and showed a 12-fold overexpression when MF2 was demonstrable. Of note, this case rapidly evolved to fibrosis within 1 year. Development of myelofibrosis (5) showed an increase of up to 5-fold, but in the end, only 2-fold during the development of MF1 in the 7-year follow-up. All other courses lastly retained TSP-1 overexpression of up to 3-fold (2) and 13-fold (3, 4, respectively) when compared to the control group.
Clinical correlates showed the association of increased TSP-1 mRNA level with higher platelet counts in advanced PMF Depending on the degree of myelofibrosis, PMF cases with TSP-1 mRNA expression level above the median (+) were separated from cases which expressed TSP-1 similar to the median or below (=). In advanced PMF, high TSP-1 mRNA levels were found to be associated with likewise higher platelet counts ('+' group: median, 366; range, 241-1348 The expression of TSP-1 in PMF is restricted to megakaryocytes, proplatelet formations, and platelet deposits Immunohistochemistry showed that the entire megakaryocytic lineage was strongly immunoreactive for TSP-1 in PMF. In contrast to normal bone marrow which also showed TSP-1 positive megakaryocytes adjacent to sinusoids and endothelial cells (Fig. 5e) , PMF displayed high numbers of interstitially located TSP-1 positive megakaryocytes and platelet deposits (Fig. 5a ). Of note, long pseudopodia and large proplatelet formations of PMF megakaryocytes were nicely demonstrable by TSP-1 staining (Fig. 5c) . ET showed TSP-1 positive megakaryocytes but failed to exhibit likewise positive proplatelet formations and deposition (Fig. 5d) . No TSP-1 labeling was demonstrable in endothelial cells and in fibroblasts in areas of matrix accumulation in PMF (Fig. 5a, b, respectively) . Double-immunofluorescence staining using the TSP-1 antibody and a CD105/endoglin antibody specific for endothelial cells confirmed that TSP-1 and CD105/endoglin did not co-localize in endothelial cells (Fig. 6 ). TSP-1 was exclusively demonstrable in megakaryocytes and their progenies. CD105/endoglin stained the exaggerated angiogenesis in PMF.
TSP-2 protein expression was heterogeneous with regard to staining pattern and intensity. TSP-2 staining in PMF and controls showed megakaryocytes which exhibited a weak labeling and others which were unlabelled. Since this pattern was demonstrable on the same slide, staining failures can be excluded. A prominent difference as shown for TSP-1 staining was not demonstrable by TSP-2 immunohistochemistry (therefore not shown).
Discussion
Megakaryocytes and platelets normally produce large amounts of pro-angiogenic factors allowing proliferation of endothelial cells in vitro and in vivo. However, platelets also produce factors capable for counteraction against the formation of new vessels such as platelet factor 4 or thrombospondins, i.e. most notably TSP-1. A physiologically fine-tuned pro-and anti-angiogenic balance apparently ensures the homeostasis essential for proper vascularization.
TSPs were shown to exhibit potent anti-angiogenic properties, i.e. cells deficient in TSP-1 and TSP-2 stimulate angiogenesis to a much greater extent than their normal counterparts [9] . The onset of angiogenesis in cancer often involves down-regulation of endogenous TSP-1 by ras mutated cancer cells and also in adjacent non-transformed fibroblasts but not in endothelial cells [18] .
Studies with TSP-1 knockout mice revealed that after myelosuppression, these animals quickly recovered from Fig. 4 PMF cases with TSP-1 mRNA level above median were labeled as (+) and those with TSP-1 mRNA level similar or below the median as (=). Based on the degree of myelofibrosis the two groups (+, =) were tested for a potential relation of platelet counts and TSP-1 mRNA level. Advanced PMF cases with higher TSP-1 mRNA level also had higher platelet counts Fig. 3 Follow-ups of TSP-1 mRNA level in PMF during individual courses of disease. MF dynamics are indicated by the arrow. Initial TSP-1 mRNA level at time point of diagnosis was calculated relative to the mean expression level in the control group (Fig. 1) . Different symbols represent individual follow-ups ranging from 1 to 7 years thrombocytopenia compared to wild-type animals. This fact might be attributable to the concomitantly increased angiogenesis and vessel density in the bone marrow which presented a twofold higher number of megakaryocytes in the knockout model. Subsequently, platelet numbers increased more rapidly and thrombopoiesis was restored also more quickly. Another study using TSP-2 knout out mice also showed that the pro-angiogenic effects in this model were mediated by enhanced MMP-9 action [19] .
A hallmark in bone marrow pathology of PMF is the population of enlarged and clustered megakaryocytes most likely responsible for progressive myelofibrosis and exaggerated angiogenesis. The latter is already overt in early prefibrotic stages and apparently contributes to an easy escape of progenitor cells into the periphery to colonize distant organs such as spleen.
We hypothesized that TSP might be aberrantly expressed in PMF, i.e. decreased expression could explain a contribution to two typical PMF features, the high number of megakaryocytes, and the high vessel density in PMF bone marrow.
On the other side, TSP-1 was shown to activate latent TGFβ-1 [20] , the most effective pro-fibrotic factor involved in the development of myelofibrosis and other fibrotic states [21] . In addition, TSP-1 up-regulates TIMP-1 [22] , the tissue inhibitor of metalloproteinases, whose overexpression might favor matrix accumulation and fibrosis. We recently found by an explorative low-density array profiling that TSP-1 (THBS1) was overexpressed in total bone marrow cells of advanced stage PMF [23] . The interesting action profile attracted us to study the TSP in PMF in more detail.
In the present study, TSP-1 was significantly overexpressed by bone marrow cells in PMF independently of the stage of disease, i.e. the degree of myelofibrosis. This feature discriminated from ET cases which also showed megakaryocytes increased in size and numbers but lacked up-regulated TSP-1.
To test for TSP-1 in other MPN or associated MPN/ MDS, we selected CML and CMML cases. Apart from some outliers, neither CML nor CMML showed demonstrable higher or lower levels when compared to PMF, ET, and controls. The overall stronger TSP-1 mRNA expression in CML might be attributable to the increase of (micro-) megakaryocytes demonstrable in some of these cases.
When we looked for clinical parameters and TSP-1 mRNA expression level in PMF subgroups, we found that interestingly in advanced stages, those cases with high TSP-1 mRNA expression (labeled as '+' in Fig. 4 ) also had have higher platelet counts. As expected PMF MF0 showed significantly higher platelet counts than advanced stages did. However, this only hold true for the '=' subgroup of MF2/3 cases with only moderately increased TSP-1 mRNA level.
TSP-1 protein was exclusively present in megakaryocytes in PMF including large proplatelet formations and platelet aggregates within the bone marrow interstitium. These proplatelet formations in our study group showed no association with vessels or endothelial gaps. This accumulation apart from vessels suggests a potential key role in myelofibrosis development because of the likelihood that due to fragmentation high amounts of pro-fibrotic factors could accumulate in the bone marrow as well. By contrast, a sufficient anti-angiogenic effect through TSP-1 is hard to imagine because exaggerated angiogenesis is overt in all stages and TSP-1 is apparently not acting on endothelial cells, at least TSP-1 was not detectable by two different morphological and staining approaches. By doubleimmunofluorescence labeling TSP-1 was only present in the megakaryocytes and progenies such as large proplatelet formations but not in endothelial cells (CD105 positive). TSP-1 positive proplatelets are in good agreement with a previous study which detected TSP-1 in the demarcation membrane of thrombin-stimulated human megakaryocytes [24] . The demarcation membrane is the intracellular precursor formation of pseudopodia which later mediate the continuity with the extracellular space and also delivery of platelets [25] .
Interestingly, in a previous study with mice knocked out for TSP-2, these animals failed to show a proper interaction of megakaryocytic pseudopodia and bone marrow sinuses to deliver proplatelets and platelets [13] . In our study, TSP-2 mRNA was only barely detectable except for some high outliers in advanced PMF. TSP-2 protein detection was only demonstrable in some megakaryocytes in both PMF and normal hematopoiesis but technical issues cannot be excluded with certainty as the reason for this heterogeneity. However, it was found that megakaryocytes in vitro show an uptake of extracellular TSP-2 but no intracellular de novo synthesis [13] . If so, TSP-2 positive megakaryocytes in PMF and controls are biologically different in their current state of TSP-2 uptake, and heterogeneous staining pattern was not artificial. Nevertheless, TSP-2 in our study did not sufficiently reveal its secrets in PMF pathology.
In summary, the abundance of TSP-1 in PMF has presumably three relevant issues: (1) A pro-fibrotic effect is likely, and explainable by a megakaryocytic-derived local accumulation with subsequent activation of latent TGFβ-1, increased matrix synthesis and inhibition of MMP activity. (2) The strictly morphological-based diagnosis of hypercellular, prefibrotic PMF versus ET could be supported by TSP-1 expression analysis when larger cohorts will be successfully tested for reliability of this marker in the diagnostic setting. (3) The proposed but functionally complex effect of TSP-1 on endothelial cells might be aberrant or insufficient in PMF due to overweight of other pro-angiogenic factors. However, TSP-1 could nevertheless be an excellent indicator of increased angiogenesis. Accordingly, our data fit to the recent observation that in tumor-bearing mice TSP-1 is obviously a biomarker for the Fig. 6 Merged figure from confocal laser scanning microscopy and double-immunofluorescence staining revealed TSP-1 (green) restricted to megakaryocytes and platelets and CD105/endoglin (red) restricted to endothelium. No TSP-1 could be detected in endothelial cells increased tumor angiogenesis indicating the individuals attempt to counteract against new vessel formation [26] . We conclude that TSP-1 is a promising factor in PMF useful to be considered as a biomarker for monitoring potentially targeted therapy.
